Indivior PLC (INDV.L)

1 318,00 +43,00 (+3,37 %) À la clôture : 04:51PM BST

Indivior PLC

10710 Midlothian Turnpike
Suite 125
North Chesterfield, VA 23235
United States
804 379 1090
https://www.indivior.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 1 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Mark Crossley	CEO & Executive Director	1,85M	S.O.	S.O.
Mr. Ryan Preblick	CFO & Executive Director	898,51k	S.O.	S.O.
Dr. Christian Heidbreder	Chief Scientific Officer	S.O.	S.O.	S.O.
Mr. Jason Thompson	Vice President of Investor Relations	S.O.	S.O.	S.O.
Ms. Cynthia Cetani	Chief Integrity & Compliance Officer	S.O.	S.O.	S.O.
Mr. Jeffrey W. Burris	Chief Legal Officer	S.O.	S.O.	1972
Mr. Jon Fogle	Chief Human Resources Officer	S.O.	S.O.	S.O.
Mr. Richard Simkin	Chief Commercial Officer	S.O.	S.O.	S.O.
Mr. Hillel West	Chief Manufacturing & Supply Officer	S.O.	S.O.	S.O.
Mr. Vishal Kalia	SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en GBp.

Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Indivior PLC en date du 1 juin 2024 est 7. Les scores principaux sont Audit : 10; Société : 5; Droits des actionnaires : 1; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.